Skip to main content

Collegium Pharmaceutical, Inc. (COLL)

NASDAQ: COLL · IEX Real-Time Price · USD
17.95 -0.58 (-3.13%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap620.51M
Revenue (ttm)325.78M
Net Income (ttm)103.51M
Shares Out34.57M
EPS (ttm)2.69
PE Ratio6.67
Forward PE4.73
Dividendn/a
Ex-Dividend Daten/a
Volume367,004
Open19.30
Previous Close18.53
Day's Range17.57 - 18.49
52-Week Range17.67 - 26.91
Beta0.95
AnalystsBuy
Price Target25.14 (+40.1%)
Earnings DateNov 4, 2021

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to C...

IndustryPharmaceuticals
IPO DateMay 7, 2015
CEOJoseph Ciaffoni
Employees234
Stock ExchangeNASDAQ
Ticker SymbolCOLL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is 25.14, which is an increase of 40.06% from the latest price.

Price Target
$25.14
(40.06% upside)
Analyst Consensus: Buy

News

Collegium Announces $25 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...

1 week ago - GlobeNewsWire

UPDATE: Collegium to Participate in Upcoming Conferences

STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...

2 weeks ago - GlobeNewsWire

Collegium Participate in Upcoming Conferences

STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...

2 weeks ago - GlobeNewsWire

Collegium Pharmaceutical (COLL) Misses Q3 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -76.09% and -6.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...

3 weeks ago - Zacks Investment Research

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

Collegium to Host Conference Call to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update

STOUGHTON, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, announ...

1 month ago - GlobeNewsWire

6 High Earnings Yield Picks That You Shouldn't Miss Out On

Reap handsome rewards by investing in high earnings yield stocks including MT, MTH, SIMO, DFIN, IRWD, and COLL.

Other symbols:DFINIRWDMTMTHSIMO
1 month ago - Zacks Investment Research

COLL vs. ZTS: Which Stock Should Value Investors Buy Now?

COLL vs. ZTS: Which Stock Is the Better Value Option?

Other symbols:ZTS
2 months ago - Zacks Investment Research

Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference

STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today...

2 months ago - GlobeNewsWire

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today...

2 months ago - GlobeNewsWire

Collegium Stock Is Getting Beaten As Q2 Earnings Miss Street Estimates; Revises FY21 Guidance

Collegium Pharmaceutical Inc (NASDAQ: COLL) reported Q2 adjusted EPS of $0.27, below the consensus of $0.36. The reported EPS of $1.79 was up from $0.23 a year ago and included a one-time non-cash adjus...

3 months ago - Benzinga

Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Miss Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -20.59% and -1.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million

– Xtampza ® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 –

3 months ago - GlobeNewsWire

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update

STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 202...

4 months ago - GlobeNewsWire

Collegium Announces Publication of Real-World Data in Journal of Pain Research

STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...

5 months ago - GlobeNewsWire

Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid Crisis

The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.

Other symbols:HRTX
5 months ago - The Motley Fool

Collegium to Participate in Upcoming Investor Conference

STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today a...

6 months ago - GlobeNewsWire

Collegium Pharmaceutical (COLL) Beats Q1 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Collegium Reports Record Quarterly Revenue of $87.7 Million

– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 –

6 months ago - GlobeNewsWire

Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update

STOUGHTON, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 6,...

7 months ago - GlobeNewsWire

Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million

– 2020 First Full-Year of Profitability, Driven by Xtampza ® ER Revenue Growth and the Nucynta ® Acquisition –

9 months ago - GlobeNewsWire

Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update

STOUGHTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, Februar...

9 months ago - GlobeNewsWire

Why Collegium Pharmaceutical Rose Nearly 10% on Tuesday

It's not every day that a company graduates to a slot in a high-profile stock index.

9 months ago - The Motley Fool